Orientador: Osvaldir Pereira Taranto / Tese (doutorado) - Universidade Estadual de Campinas, Faculdade de Engenharia Química / Made available in DSpace on 2018-08-24T08:42:32Z (GMT). No. of bitstreams: 1 Souza_LucianeFranquelinGomesde_D.pdf: 6876440 bytes, checksum: af8ca21982a85f9a31f3f9b1ff3eafdc (MD5) Previous issue date: 2013 / Resumo: Microgrânulos (pellets) são formas farmacêuticas que apresentam vantagens biofarmacêuticas e, além disso, são apropriadas para aplicação de revestimento. O nifedipino é uma droga praticamente insolúvel em água, com solubilidade menor que 10 ?g/mL, de baixa e irregular biodisponibilidade depois da administração oral. Muitas pesquisas vêm sendo realizadas a fim de melhorar a solubilidade de drogas pouco hidrossolúveis fazendo o uso de desintegrantes. No Brasil, atualmente, apenas um laboratório produz comprimidos contendo nifedipino com perfil de liberação prolongada. Neste trabalho, pellets de nifedipino com matriz de liberação prolongada foram produzidos por extrusão-esferonização, e em seguida, receberam um recobrimento em leito Wurster com suspensões poliméricas de liberação imediata disponíveis no mercado, Opadry® e Opadry®II. O estudo dos processos de recobrimento foi realizado por meio de um planejamento experimental completo de dois fatores em dois níveis (22) e repetição no ponto central, para cada polímero. As variáveis estudadas foram a temperatura do ar de entrada e a vazão da suspensão de revestimento. A fração de aglomerados e a eficiência do processo foram as variáveis respostas analisadas. A temperatura do ar foi a variável que mais influenciou a eficiência do processo para ambos os polímeros e a vazão de suspensão foi o fator que mais influenciou na aglomeração durante o processo de recobrimento. Os valores de eficiência no estudo do processo se mostraram mais elevados quando o processo de recobrimento foi realizado com a suspensão polimérica Opadry®II, chegando a atingir 98%. Os pellets revestidos foram submetidos a testes de teor, dissolução in vitro e estabilidade. Os microgrânulos recobertos não tiveram o perfil de liberação prolongada alterado com os revestimentos adquiridos para ambos os polímeros. Os teores de ativo obtidos experimentalmente nos pellets mostraram-se ligeiramente inferiores aos incorporados na mistura de pós e muito próximos aos calculados pelo balanço material. Nos testes de estabilidade (40 ºC e 75% Hr) os pellets com e sem recobrimento mostraram-se estáveis quanto ao teor de ativo, perfil de dissolução e aspectos visuais. Entretanto, quando submetidos à exposição direta da luz do dia e fluorescente, os pellets recobertos perderam apenas 5% do teor, enquanto que os sem recobrimento perderam mais de 40% / Abstract: Pellets are dosage forms that have many biopharmaceutical advantages and, moreover, they are suitable for coating application. The nifedipine is a drug practically insoluble in water, with solubility of less than 10 µg/mL, low and irregular bioavailability after oral administration. Many studies have been performed in order to improve the solubility of slightly soluble drugs by the use of disintegrating. In Brazil, currently only one laboratory produces nifedipine extended release tablets. In this study, nifedipine extended release pellets were produced by extrusion-spheronization, and then received a coating layer with commercially available aqueous polymers, Opadry® and Opadry®II, in a fluid bed coater with a Wurster insert. The study of the coating processes were performed by means of a complete experimental design of two factors at two levels (22) and repetition at the central point for each polymer. The variables studied were the inlet air temperature and the coating suspension flow rate. The agglomerate fraction and process efficiency were the response variables analyzed. The air temperature was the variable that most influenced the efficiency of the process for both polymers and suspension flow rate was the most important factor involved in the agglomeration during the coating process. The process efficiency proved to be higher when the coating process was carried out with polymeric suspension Opadry ® II, reaching up to 98%. The coated pellets were tested for content, in vitro dissolution and stability. The coating layer acquired by the pellets has not changed their release profile. The nifedipine contents obtained experimentally were slightly lower than those incorporated in the mixture of powders and similar to those calculated by material balance. Not even the drug content and the release profiles were significantly affected by storage at 40 ºC and 75% relative humidity. However, when submitted to exposure to direct daylight and fluorescent light, the coated pellets lost only 5% of the drug content, while the uncoated lost more than 40% / Doutorado / Engenharia de Processos / Doutora em Engenharia Quimica

Abstract not available

Not available / text

A growing number of therapeutic compounds currently being developed by pharmaceutical companies are poorly water soluble leading to limited and/or erratic bioavailability. The rate limiting step for absorption of these compounds is dependent on the dissolution and apparent solubility. Nanoparticle formation has been exploited as a method to improve the bioavailability of these poorly water soluble active pharmaceutical ingredients (API) by increasing the dissolution rates and apparent solubilities. The influence of hydrophilic stabilizers in powder compositions prepared by the spray freezing into liquid (SFL) process using either an emulsion feed dispersion or organic co-solvent feed solutions on enhancing the wetting and dissolution properties of nanostructured aggregates containing itraconazole (ITZ). Subsequently, an in vivo pharmacokinetic study was conducted comparing the SFL processed powder to commercial Sporanox®. An ultra-rapid freezing (URF) technology has been developed to produce high surface area powders composed of solid solutions of an active pharmaceutical ingredient (API) and a polymer stabilizer. Rapid freezing technologies are known to enhance the physico-chemical properties of APIs and thus increase bioavailability. However, the effect of the different freezing geometries and rates in the URF process are unknown. Therefore, this study investigated how solvent properties and thin film geometry of the droplet affect the freezing rate and thus the physico-chemical properties of micronized danazol powders. Amorphous nanoparticles containing tacrolimus (TAC) in a solid dispersion were prepared using the Ultra-rapid Freezing (URF) process. The objective of this study was to assess the effects of combinations of polymeric stabilizers on the maximum degree and extent of supersaturation of TAC. An attempt to establish if an in vitro-in vivo correlation exists between supersaturation and improved pharmacokinetic parameters for orally dosed TAC was performed. Enteric solid dispersions could overcome limitations of premature precipitation of supersaturated solutions by 1.) delaying dissolution until the compound enters the intestines where absorption is favored and 2.) increasing the apparent solubility at higher pH to increase the driving force for absorption. The objective of the study is to investigate the influence of composition parameters including drug:polymer ratio and polymer type, and particle structure of enteric solid dispersions on the release of ITZ. / text

When considering oral administration, drug release from its pharmaceutical form and its dissolution into gastrointestinal fluids generally precedes absorption and systemic availability. The solubility-dissolution behaviour of a drug is frequently the rate-limiting step to absorption of drugs from the gastrointestinal tract (BCS class II drugs). Poor aqueous solubility has always been a very challenging obstacle as it is, together with membrane permeability, an essential factor in the limitation of a drug’s bioavailability following oral administration. Since an increasing number of newly developed drug candidates in pre-clinical development phases present poor water-solubility characteristics, there is a great need for formulation approaches to overcome this factor.<p><p>Out of the many ways to increase a product’s solubility/dissolution rate characteristics with the aim of enhancing its oral bioavailability, drug formulation as nanoparticles has received much-increased interest over the last decade. The hypothesis behind dissolution rate enhancement, considering drug particle size reduction to nanometer range, lies primarily in a much-increased effective surface area (Noyes-Whitney) presented by the resulting drug nanoparticles. Out of the various technologies available for drug particle size reduction to nanometer range, milling using high pressure homogenization is regarded as one of the simplest and most effective techniques. High pressure homogenization is a solvent-free process and is relatively rapid (time-saving). Furthermore, and most importantly, the scaling up of this technique is already established; processing capacities ranging from 3 l/h (e.g. EmulsiFlex C3®: minimum sample volume - 10 ml) to 1000 l/h (e.g. EmulsiFlex C1000®: minimum sample volume - 2 l).<p><p>Four model drugs were studied in this work. Nifedipine (NIF), an extensively studied poorly water-soluble drug in the literature, was used as the main model on which most of the development was done. In parallel to the work carried out on NIF, three UCB S.A. molecules currently under development were also studied as poorly water-soluble drugs: these being ucb-35440-3, UCB-A and UCB-B (salt of UCB-A). These three UCB S.A. model drugs are, contrarily to NIF, predicted highly dosed drugs and are weak bases, and thus present pH-dependent solubility profiles, which allowed us to investigate model drugs with different profiles.<p><p>Firstly, investigations regarding appropriate formulation development (stabilizer (surfactant) selection) and appropriate high pressure homogenization operating conditions (pre-milling cycles, influence of the number of high pressure homogenizing cycles, influence of homogenizing pressure, influence of sample temperature) were made. It has been shown, through this development, for the four studied model drugs, that high pressure homogenization is an appropriate technique for reducing drug particle size to nanometer range (NIF &61566; 290 nm, ucb-35440-3 &61566; 180 nm, UCB-A &61566; 350 nm and UCB-B &61566; 250 nm). Investigations regarding water-removal from the nanosuspensions obtained and most importantly regarding the redispersion characteristics of the retrieved powders (i.e. nanoparticles) were then carried out. In that regard, it has been shown that the presence of carriers in the formulation is essential for limiting nanoparticles agglomeration during the water-removal operation.<p><p>Drug crystalline state characterizations before and following particle size reduction were then carried out on the three studied model drugs, mainly through DSC and PXRD studies. In fact, one of the advantages of this particle size reduction approach (using high pressure homogenization), versus other frequently studied solubility/dissolution rate enhancement technologies (e.g. such as solid dispersions), is that original crystalline state shall not be altered in such a way that the achieved increased solubility and dissolution rate characteristics do not rely on the presence of the amorphous form of the drug; this furthermore implying a greater time-stability of the developed formulations. Through the data obtained, it has been shown that original drug crystalline state seems to be unaltered following particle size reduction.<p><p>In vitro solubility and dissolution characteristics were then evaluated on the formulations developed in order to verify the posed hypothesis regarding effective surface area increase. It has been shown through these studies that drug solubility and most importantly drug dissolution rate can be significantly enhanced for nanoparticulate systems (verified for NIF, ucb-35440-3, UCB-A and UCB-B). For example, solubility was enhanced from 26 µg/ml vs. 19.5 µg/ml for NIF nanoparticles and the dissolution characteristics showed that 100% of the tested dose (equivalent to 10 mg NIF) was already dissolved following 10 min vs. less than 5% for un-milled NIF. Following these very interesting and promising results, and preliminary to the in vivo pharmacokinetic studies carried out, in vitro permeation studies (apical to basolateral transfer studies) across intestinal cell models (Caco-2 and HT29-5M21 cultures and co-cultures) were carried out. This evaluation was only carried out using NIF as a model drug and showed a 6-fold increase in the permeation rate for NIF nanoparticles. The influence of chitosan (permeability enhancer/bioadhesive polymer) in the NIF nanoparticle formulation with regard to in vitro NIF permeation rate was also evaluated.<p><p>In vivo pharmacokinetic studies in rats were conducted using NIF and ucb-35440-3 as model drugs. The very different profiles of these two model drugs allowed us to retrieve interesting information regarding the in vivo behaviour of the developed formulations. As expected from the in vitro (i.e. solubility/dissolution/permeation) studies and results obtained for NIF, an increased extent of exposure could be observed for NIF nanoparticles versus un-milled NIF; the difference being more pronounced when the formulations were orally administered into capsules (2.5-fold increase in extent of exposure and 6-fold increase in Cmax). For ucb-35440-3, a poorly water-soluble weak base with a reported significant food effect considering oral bioavailability, an increased extent of exposure for nanoparticles, versus the un-milled drug, could only be observed in fasted state (4-fold increase in extent of exposure and 2.7-fold increase in Cmax). These different, diet-relative observations allowed us to put forward some limitations and precautions (considering poorly water-soluble weak bases) relative to the possibility of drug reprecipitation following stomach’s exiting, particularly if dissolution in the stomach is quite fast (e.g. nanoparticulate systems).<p><p>In parallel to the in vivo pharmacokinetic evaluation of NIF nanoparticles, evaluation of the antihypertensive effect of the systems developed following oral administration, using spontaneously hypertensive rats, was also carried out and compared to un-millled NIF. The results obtained showed a significant drop in systolic blood pressure for NIF nanoparticles (32% reduction of initial SBP following 30 min vs. 1% for un-milled NIF) and nicely complemented the in vitro and in vivo results obtained for NIF nanoparticles.<p><p>Finally, a stability study of the optimized NIF nanoparticle formulation was carried out with respect to reported ICH conditions (25°C/60% RH; 30°C/65% RH; 40°C/75% RH). The results showed that the studied NIF nanoparticle formulation retains all its original characteristics (dissolution, crystalline state, redispersion characteristics); this being verified over time (12 months) and for each of the three storage conditions studied.<p> / Doctorat en sciences pharmaceutiques / info:eu-repo/semantics/nonPublished

Thesis (M. Pharmacy ((Pharmaceutics)) -- University of Limpopo, 2022 / According to the biopharmaceutical classification system, Clarithromycin is considered a class II molecule with low solubility. Poorly soluble drugs result in low bioavailability. Various techniques have been studied to improve the solubility of drugs and subsequently bioavailability. Of these techniques, preparation of amorphous form is the preferred method because it is a more effortless and convenient way to improve the aqueous solubility and dissolution of poorly water soluble drugs. The only disadvantage of amorphous materials is that they are less thermodynamically stable and can recrystallize during processing and storage. Aim: The aim of this study is to prepare amorphous form of clarithromycin to improve its solubility, dissolution rate, and, subsequently, bioavailability. Methods: In this study, preparation of amorphous form of clarithromycin was conducted using the quench cooling method in which the purchased anhydrous crystalline clarithromycin was spread on an aluminum foil and heated to a melting point (217˚C - 220˚C) and then rapidly cooled. Various techniques were conducted to characterize the prepared amorphous clarithromycin, and these include Differential Scanning Calorimetry (DSC), Fourier-Transform Infrared Spectroscopy (FTIR), and X-Ray Powder Diffraction (XRPD). In addition, tablets were formulated using the amorphous clarithromycin mixed with selected excipients from compatibility studies, and in vitro dissolution and stability studies were conducted over a period of 6 months. Results: The DSC thermogram results confirmed that the material prepared using the quench cooling process is an amorphous solid-state. Furthermore, the XRPD confirmed an amorphous solid-state with scattering halo peaks. The FTIR also depicted some broader and lower intensity peaks that indicated a formation of an amorphous material. The dissolution rate of amorphous clarithromycin tablets improved by more than 30% when compared to commercial crystalline clarithromycin tablets. The study revealed a drop in dissolution rate at months 3 to 6 under accelerated conditions due to recrystallization. The 6 monthly stability study at long term conditions showed no change in the integrity of the tablets and their contents. Conclusion: As indicated by the study, it can be concluded that the amorphous clarithromycin remained stable during processing and storage under long-term stability for 6 months. Furthermore, based on dissolution results, it can be concluded that amorphous solids have an improved dissolution rate. / Medical Research Council CHIETA

Parmi toutes les voies d’administration, la voie orale a toujours suscité un grand intérêt. Les formes prises par voie orale présentent une grande facilité d’administration pour le patient, tandis que pour les chercheurs, la physiologie du système gastro-intestinal peut être facilement modélisable. Malheureusement, son importante variabilité, liée principalement au temps de vidange gastrique, peut conduire à une mauvaise reproductibilité des effets thérapeutiques et à une diminution de la biodisponibilité. Ce problème est surtout rencontré dans le cas des principes actifs présentant une fenêtre d’absorption étroite au niveau de l’intestin supérieur [Deshpande et col. 1996]. Une solution a été de développer des formes galéniques à libération prolongée caractérisées par un temps de résidence gastrique accru. Ainsi, le principe actif est libéré progressivement en amont de sa fenêtre d’absorption. Dans cette optique, plusieurs systèmes ont été développés :des formes bioadhésives, expansibles, gonflantes ou à hautes densités [Singh et Kim, 2000]. Mais parmi toutes ces formes, ce sont les systèmes flottants qui semblent offrir la protection la plus efficace contre une vidange gastrique précoce [Moës, 1989]. Seth et Tossounian ont ainsi développé une gélule flottante à libération prolongée, basée sur le gonflement d’un dérivé cellulosique. Etant une forme monolithique, sa vidange gastrique était soumise au phénomène de tout ou rien. De plus, cette forme présentait un inconvénient majeur puisqu’elle était sujette à des fractionnements intra-gastriques, diminuant de ce fait la reproductibilité inter- et intra-individuelle [Seth et Tossounian, 1984]. <p>\ / Doctorat en Sciences biomédicales et pharmaceutiques / info:eu-repo/semantics/nonPublished